BioXcel removes CEO Vimal Mehta from his posts, Samir Saleem named president
BioXcel Therapeutics ends the roles of four officers, including its CEO, effective October 31, 2026. Details are based on a report from TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
BioXcel Therapeutics will end the roles of four officers effective October 31, 2026, according to TradingView, which cites filings made with the SEC. The group includes CEO and President Vimal Mehta, CFO Richard Steinhart, Chief Scientific Officer Frank Yocca and Chief Legal Officer Javier Rodriguez.
Mehta will remain on the board of directors and will receive $5,000 per month starting November 1, 2026. Samir Saleem, the company's Chief Restructuring Officer, has been appointed president and secretary. The company cites the sale and wind-down of its affairs as the reason for the changes.
why it matters
For investors, this is mainly a signal that the company is moving toward winding down its business. A leadership change alongside an asset sale and restructuring typically points to liquidation or payments to shareholders, though the filing does not disclose the details of that process.
tags
instruments
sources
- BioXcel Therapeutics terminates CEO Vimal Mehta; Samir Saleem named president — TradingView, 30 October 2026 at 21:23 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗